Tofacitinib: A Review in Rheumatoid Arthritis
Tofacitinib: A Review in Rheumatoid Arthritis
About this item
Full title
Author / Creator
Publisher
Cham: Springer International Publishing
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer International Publishing
Subjects
More information
Scope and Contents
Contents
Tofacitinib (Xeljanz
®
) is a potent, selective JAK inhibitor that preferentially inhibits Janus kinase (JAK) 1 and JAK3. In the EU, oral tofacitinib 5 mg twice daily is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant of, one or more...
Alternative Titles
Full title
Tofacitinib: A Review in Rheumatoid Arthritis
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1964698218
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1964698218
Other Identifiers
ISSN
0012-6667
E-ISSN
1179-1950
DOI
10.1007/s40265-017-0835-9
